Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FB CD22 (Clusters of Differentiation 22) inhibitors
L01FB02 Moxetumomab pasudotox
D09932 Moxetumomab pasudotox (USAN/INN)
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Anti-CD22 Antibodies
Moxetumomab Pasudotox
D09932 Moxetumomab pasudotox (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: Ig superfamiy
SIGLEC family
CD22 (SIGLEC2)
D09932 Moxetumomab pasudotox (USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09932
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09932
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09932
